Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
331. |
ECCT/16/12/03 | The Partners Scale-Up Project An implementation project to scale-up delivery of antiretroviral-based HIV-1 prevention among Kenyan HIV-1 serodiscordant couples |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya 1. Thika Level 5 Hospital, Ruiru Sub-County Hospital, Kiambu County Hospital, Kikuyu PCEA Hospital (Kiambu county) 2. Coptic Hospital, Mbagathi Hospital, St. Mary\'s Hospital, Pumwani Maternity Hospital (Nairobi City county) 3. Nyeri PGH, Karatina Sub-County Hospital, (Nyeri county) 4. Kerugoya County Hospital (Kirinyaga county) 5. Murang\'a County Hospital (Murang\'a county) |
View |
332. |
ECCT/16/12/02 | Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial. |
Principal Investigator(s) 1. ISAAC TSIKHUTSU Site(s) in Kenya KEMRI/WRP, KERICHO |
View |
333. |
ECCT/16/12/01 | The Partners Scale-Up Project Animplementation project to scale-up delivery of antiretroviral-based HIV-1 prevention amongKenyan HIV-1 serodiscordant couples. |
Principal Investigator(s) 1. Prof. Elizabeth Ann Bukusi Site(s) in Kenya 1. KISUMU SITE (Kisumu county) 2. Thika Site (Kiambu county) |
View |
334. |
ECCT/16/11/05 | RV 456: Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo A randomized, obsever-blind, placebo controlled, two-part, Phase 2 study to evaluate the Safety, Tolerability and Immunogenicity of Two prime-boost regimen of the candidate Prophylactic vaccines for Ebola Ad26-ZEBOV and MVA-BN Filo. |
Principal Investigator(s) 1. Fredrick Kipyego Sawe Site(s) in Kenya 1. KEMRI/WRP Kericho (Kericho county) 2. KEMRI/WRP Kombewa, Kisumu (Kisumu county) |
View |
335. |
ECCT/16/11/04 | RV456 A Randomized, Observer-blind, Placebo-controlled, Two part, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo |
Principal Investigator(s) 1. JANET OYIEKO Site(s) in Kenya KOMBEWA CLINICAL RESEARCH CENTRE |
View |